Dawn Health, in collaboration with Novartis, has introduced Cora BC, a new app designed to support breast cancer patients throughout their treatment journey. The app will initially launch in Germany before expanding to the UK, Canada, Australia, and other markets.
Cora BC offers several key features to help patients manage their care, including health tracking tools with intuitive graphs, personalized medication and appointment reminders, and curated content tailored to individual patient needs. The app also includes diary functionality and consultation preparation tools to facilitate more productive discussions with healthcare providers.
“Cora BC is more than a tool—it’s a step toward better care,” said Alexander Mandix Hansen, CEO of Dawn Health. “By partnering with Novartis, we’re ensuring breast cancer patients have access to the resources and support they need to feel seen, heard, and empowered to achieve the best possible outcomes. This app reflects our shared commitment to innovation and patient-centric care.”
While not intended for medical advice, diagnosis, or treatment recommendations, the app aims to help users organize their care and improve communication with healthcare providers. The launch builds on Dawn Health and Novartis’ existing partnership, which has previously produced Ekiva MS and Ekiva PNH.
Dawn Health, a global digital health company, specializes in software as medical device (SaMD) and digital therapeutics (DTx). The company focuses on accelerating digital solutions to market through its product platform, working with life science industry partners to create digital health products for people with chronic conditions.
